Sign In
Buy DTCFF
$0.299
+0.0178 (+6.31%)
At Close: Jul 31, 2026
Defence Receives FDA Approval for Phase I Clinical Trial Targeting Solid Cancer Tumors with AccuTOX(R)
11:27am, Monday, 11'th Dec 2023
Vancouver, British Columbia--(Newsfile Corp. - December 11, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechn
Vancouver, British Columbia--(Newsfile Corp. - November 14, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechn
Defence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine Technology
03:15am, Tuesday, 07'th Nov 2023
Vancouver, British Columbia--(Newsfile Corp. - November 7, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical compa
Defence's AccuTOX(R) And Antigen Cross-Presentation: Discovery Leads Towards the Development of a Groundbreaking Platform
03:15am, Wednesday, 25'th Oct 2023
Vancouver, British Columbia--(Newsfile Corp. - October 25, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a leading Canadian biopharmaceutic
Defence's Novel Accutox(TM) Continues to Surprise on Results Against Cancer
03:15am, Wednesday, 18'th Oct 2023
Vancouver, British Columbia--(Newsfile Corp. - October 18, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company
Vancouver, British Columbia--(Newsfile Corp. - October 10, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company developing va
Defence to Present Three of Its Leading Products at the Upcoming Festival of Biologics in Basel, Switzerland
06:00pm, Friday, 06'th Oct 2023
Vancouver, British Columbia--(Newsfile Corp. - October 6, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company s
RETRANSMISSION: Defence to Present at the 9th Annual Immuno-Oncology 360º Summit in New-York February 7-10, 2023
03:15am, Monday, 23'rd Jan 2023
Vancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company
Defence To Present at The 9th Annual Immuno-Oncology 360 Summit in New-York February 7-10, 2023
04:30pm, Friday, 20'th Jan 2023
Vancouver, British Columbia--(Newsfile Corp. - January 20, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company
DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER
03:00pm, Wednesday, 16'th Feb 2022 InvestorsHub
DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER Vancouver, BC, Canada, February 16th, 2022 -- InvestorsHub NewsWire Defence Therapeutics Inc. ("Defence" or the "Company"), (CSE:DTC, USOTC:DTCFF) a pre-clinical biotechnology company developing various products for the immune-oncology space, is pleased to announce the establishment of an agreement with Cato SMS, to advise on the submission of its clinical application to Health Canada in order to i...
Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9
01:49pm, Wednesday, 26'th Jan 2022 InvestorsHub
Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9
Vancouver, BC, Canada, January 26th, 2022 - InvestorsHub NewsWire - Defence Therapeutics Inc. ("Defence" or the "Company" CSE:DTC, USOTC:DTCFF), a pre-clinical biotechnology company developing various immune-oncology products, is pleased to announce the development of AccuVAC-PT009, a new protein-based HPV vacc...
DEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENT
05:32pm, Tuesday, 30'th Nov 2021 InvestorsHub
Vancouver, BC, Canada -- November 30th 2021 -- InvestorsHub NewsWire -- Defence Therapeutics Inc. (CSE: DTC; FSE: DTC; USOTC: DTCFF) ("Defence" or the "Company"), is a publicly-traded biotechnology company working on engineering the next generation vaccines, Antibody Drug Conjugates, ADC products, and cancer therapeutics using its proprietary AccumTM platform. The core of Defence Therapeutics platform is its AccumTM technology, which enables pre...
DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER
01:24pm, Tuesday, 23'rd Nov 2021 InvestorsHub
DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER
Vancouver, BC, Canada -- November 23, 2021 -- InvestorsHub NewsWire -- Defence Therapeutics Inc. ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines is pleased to announce the establishment of an agreement with the Lady Davis Institute cell processing center (CPC) to initiate manufacturing of...
